Repurposed drug has promising efficacy in non-small cell lung cancer
An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) with KRAS mutations, a clinical trial led by UT Southwestern Harold…